Greenwood Village

Researchers are evaluating changes in bone mineral density in premenopausal women with heavy menstrual bleeding caused by uterine fibroids or moderate-to-severe pain from endometriosis. This Phase 3B, open-label study looks at the effects of continuous treatment with a relugolix combination tablet for up to 48 months 4 years, followed by a 1-year period to monitor bone health after stopping treatment. Participants will take a daily oral relugolix combination tablet containing relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg for 4 years. Bone mineral density will be measured every 6 months using dual-energy X-ray absorptiometry DXA. Some women who have completed a previous related study may join to complete 3 years of treatment. After treatment ends, bone density will be checked again at 6 months and 12 months during the follow-up year. Women in the study will have regular visits for bone density scans and health assessments, including physical and gynecological exams, lab tests, and vital signs. Researchers will track changes in bone density at the spine, hip, and femoral neck throughout treatment and follow-up. They will also monitor for any fractures or adverse events during the 4 years of treatment and the 1-year post-treatment period. Total participation can last up to 5 years including the follow-up.

Researchers are evaluating the safety and preliminary effects of a single intradiscal injection of BRTX-100 in adults with chronic lumbar disc disease, a condition causing back and leg pain due to degeneration of spinal discs confirmed by imaging and clinical evaluation. This is a phase 2, double-blind, randomized study with controlled and blinded assessments to compare BRTX-100 against a sham procedure treatment. Participants will be randomly assigned to receive either BRTX-100, which contains specially cultured stem cells from their own bone marrow combined with platelet lysate, or a control group receiving a sham procedure with saline. Those in the treatment group will undergo bone marrow collection to prepare the BRTX-100 injection, while the control group will have bone marrow and blood collected but will not receive the active injection. The study includes a Safety Run-In phase with close monitoring of the first four treated participants before continuing the randomized phase. Follow-up visits will occur at weeks 2, 12, 26, 52, and 104 or early termination. During the study, participants will be monitored through physical exams, lab tests, and safety assessments to track any adverse effects and evaluate treatment impact. Primary safety measures will be assessed from baseline through week 104, and efficacy will be evaluated through week 52. The study aims to gather detailed information on safety and initial effectiveness while participants continue regular evaluations over two years, with careful oversight by medical monitors and a data safety board.

Researchers are evaluating the safety and effects of two study medicines, PF-07275315 and PF-07264660, for treating moderate to severe atopic dermatitis AD, a long-lasting itchy red rash caused by a skin reaction. The study includes adults aged 18 years or older who have had AD confirmed for at least six months and have not responded effectively to topical treatments. The study is a Phase 2 randomized, double-blind, placebo-controlled trial sponsored by Pfizer. The study consists of multiple stages. In Stage 1, participants received PF-07275315, PF-07264660, or a placebo for 12 weeks. Stage 2 involves PF-07275315 or placebo injections over 12 weeks. Stage 3 includes participants who previously received anti-inflammatory proteins, with treatment lasting up to 32 weeks. Stage 4 involves PF-07264660 or placebo injections for 12 weeks. All injections are given as multiple shots in a clinic setting. Participants will be in the study for up to 40 weeks in Stages 1, 2, and 4, and up to 52 weeks in Stage 3. Researchers will monitor skin improvements using measures such as the EASI75 score, which reflects a 75% improvement in eczema severity, along with other skin assessments, vital signs, ECG, and laboratory tests. Safety and treatment effects will be closely observed throughout the study period.

Researchers are evaluating the safety and effectiveness of the ReGelTec HYDRAFIL System for adults with axial chronic low back pain caused by degenerative disc disease DDD. This study focuses on participants who continue to experience severe back pain and dysfunction after at least six months of non-surgical conservative care. The trial is a multicenter, prospective, dual-arm, randomized controlled pivotal study designed to provide important data on this treatment device. Participants are divided into two groups one group receives continued conservative medical management plus a percutaneous hydrogel spinal implant delivered by the HYDRAFIL System, while the other group continues conservative care with a sham procedure involving needle insertion without implant delivery. After 24 months, participants in the control group may crossover to receive the hydrogel implant if they qualify. The study involves delivering an injectable hydrogel implant to the lumbar discs to address degeneration. During the study, participants will be monitored regularly and assessed for clinical success, including symptom improvement over a 12-month period. Evaluations will include imaging and clinical assessments to measure outcomes. Participants must comply with follow-up schedules and complete required forms. The total study duration extends through 2028, allowing long-term observation of safety and effectiveness.

Researchers are establishing the Integrated Cancer Repository for Cancer Research iCaRe2 as a multi-institutional resource to collect and manage standardized, multi-dimensional, and longitudinal data and biospecimens from adult cancer patients, individuals at high risk, and normal controls. This resource covers a wide geographical area including small and rural hospitals and cancer centers. The goal is to advance comprehensive studies on cancer risk factors and enable development of new strategies for cancer prevention, screening, early detection, and personalized treatment. The iCaRe2 resource collects data and biospecimens such as tumor samples, germline DNA, serum, urine, and plasma from participants across multiple cancer registries covering various cancer types. It operates as a web-based, HIPAA-compliant platform allowing centers with different expertise to contribute and collaborate. This repository supports cohort and population studies by providing a secure, standardized, and interoperable system for cancer-related data collection and sharing. Participants include adult patients with cancer, individuals at risk, and normal controls who can provide informed consent. Data collected includes clinical information, biospecimens, and longitudinal follow-up. The study measures include the development and implementation of the web-based registry and banking of biological materials for future research. Participation involves consent and data contribution, with monitoring and data validation ensuring quality. The repository enables ongoing research collaborations to study cancer biology, genetics, epidemiology, and patient care.

Researchers are comparing the rates of surgical and minimally invasive interventions, as well as any harms, in Medicare beneficiaries treated with the MILD procedure versus those treated with interspinous process decompression IPD for lumbar spinal stenosis with neurogenic claudication. This observational study uses Medicare claims data to follow patients for 24 months after their initial procedure starting from January 1, 2017. The purpose is to evaluate outcomes between these two types of procedures without requiring prior patient enrollment or consent. The study includes two groups patients who received MILD, which is a percutaneous image-guided lumbar decompression performed under fluoroscopic guidance through a dorsal approach to the spine, and patients who received IPD, a different device-based decompression procedure. Data on reoperations and complications will be collected for both groups over a 24-month follow-up period using Medicare claims. Enrollment continues until the sponsor decides to stop. Participants involvement is passive as the study uses existing Medicare claims data. Researchers will monitor rates of harms related to the initial procedure and subsequent surgical or minimally invasive interventions over two years. No direct patient visits or interventions are conducted, and the study is exempt from institutional review board oversight. The total study duration extends to December 2026, covering cases treated since early 2017.

Researchers are evaluating LUM-201 as a treatment for Pediatric Growth Hormone Deficiency PGHD in children who have not previously received treatment. This Phase 3 trial aims to validate the LUM-201 predictive enrichment marker strategy to identify children most likely to benefit from daily oral LUM-201 therapy. The study focuses on prepubertal children with impaired growth caused by growth hormone deficiency. Participants will be randomly assigned to receive either LUM-201 or a matching placebo by mouth once daily. LUM-201 is given at a dose of 1.6 mgkgday. This randomized, double-blind, placebo-controlled study lasts for 12 months. The trial compares annualized height velocity AHV after 12 months of treatment between the two groups. During the study, children will undergo regular assessments of growth and hormone levels to monitor response to treatment. Researchers will measure height velocity over 12 months to evaluate the effect of LUM-201 compared to placebo. The trial includes safety monitoring and aims to complete participant involvement by January 2028.

Researchers are studying the safety and effectiveness of SL1002 injectable solution for treating knee pain in adults with mild to moderate osteoarthritis of the knee. This randomized, double-blind, placebo-controlled Phase III trial compares a single dose of SL1002 against a placebo to better understand its impact on knee pain. Participants will receive either a single injection of SL1002 or a placebo normal saline in a randomized order. The study uses a quadruple masking method to keep participants and researchers unaware of treatment assignments. The treatment is given once, and the effects on knee pain are observed over a 12-week period. Throughout the study, participants will be evaluated regularly to measure changes in daily pain intensity while walking. Researchers will monitor safety, compliance, and response to treatment using pain questionnaires and diagnostic nerve blocks. The main outcome is the change in average daily pain from the start of the study to 12 weeks after treatment. The trial is sponsored by Saol Therapeutics Inc and will last from November 2025 to February 2027.

Researchers are conducting a global, prospective, multi-center observational study to gather real-world data on the long-term effectiveness, economic value, and technical performance of Boston Scientifics commercially approved neurostimulation systems for pain management. The study focuses on patients using these neurostimulation devices according to their approved instructions for use in routine clinical practice. Participants will first undergo a neurostimulation trial period using any commercially approved Boston Scientific neurostimulator for pain. Those who experience a positive outcome from this trial may then receive a permanent implant of the neurostimulation system. Treatment customization will be guided by the investigators judgment and routine care practices at each site. During the study, participants will be observed to collect information on clinical outcomes, technical device performance, and economic factors related to neurostimulation therapy. The research team will monitor participants over the long term to assess how well the therapy manages pain and its associated benefits. The study is expected to continue until May 2035, with ongoing follow-up and data collection throughout this period.

Researchers are evaluating the safety and effectiveness of VDPHL01, an investigational oral drug, in female subjects with Androgenetic Alopecia AGA, a genetic condition causing hair loss due to an excessive response to hormones called androgens. This Phase 3, multi-center, double-blind study aims to better understand treatment outcomes for women aged 18 to 65 with mild to moderate AGA. The study is sponsored by Veradermics, Inc. and includes about 13 months of participation with 11 scheduled visits. Participants will be randomly assigned to one of several groups receiving different regimens of VDPHL01 or placebo. Some groups take VDPHL01 twice daily BID for the entire 12 months, while others begin with placebo or a combination of VDPHL01 once daily QD and placebo before switching treatments after 6 months. The study maintains a double-blind design, meaning neither participants nor researchers know who receives the active drug or placebo during the first 6 months. Throughout the study, participants will attend visits for screening, baseline assessment, and follow-ups at weeks 2, months 1, 2, 4, 6, 8, 10, 12, and 13. Researchers will evaluate hair counts in target areas at 6 months and participants own assessment of treatment benefit. Participants agree to maintain consistent hair length, style, and color, and will have a small tattoo placed on their scalp for photographic monitoring. Safety and treatment effects will be carefully monitored during the study period.